Licence extension for secukinumab covering axial manifestations of psoriatic arthritis approved in EU

Approval is based on data from the phase IIIb MAXIMISE trial (n=485), which met both of its primary and key secondary endpoints, with 62.9% and 66.3% of patients treated with 300mg and 150mg versus 31.3% on placebo achieving the primary endpoint (ASAS20 response), respectively.

PharmaTimes